| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4706 | Sgk1 Inhibitor 17a | Novel highly selective SGK1 inhibitor with a highly optimized profile suitable for oral dosing as a potentially disease-modifying agent for osteoarthritis |
|
| DCC4707 | Sglt1/2-in-8 | Novel Potent SGLT1/2 Dual Inhibitor |
|
| DCC4708 | Sgx393 | Novel inhibitor of the CML mutant Bcr-AblT315I, preempting in vitro resistance when combined with nilotinib or dasatinib. |
|
| DCC4709 | Sh-053-r-ch3-2’f | Selective agonist of GABA A receptors α5 subunit |
|
| DCC4710 | Sh-053-s-ch3-2'f | Potent and selective agonist of GABAA receptors α5 subunit |
|
| DCC4711 | Sh-11037 | Novel potent sEH inhibitor, effectively blocking key angiogenic properties of human retinal endothelial cells (HRECs), inhibiting choroidal sprouting and significantly suppressing CNV lesion volume |
|
| DCC4712 | Sh-11052 | Novel inhibitor of endothelial cell growth |
|
| DCC4713 | Sh-2251 | Novel selective inhibitor of the generation of IL-5-producing Th2 cells and induction of active histone modifications at the IL5 gene locus during Th2 cell differentiation |
|
| DCC4714 | Sha 14-1 | Stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypassing drug resistances and synergizing cancer therapies in human leukemia cell |
|
| DCC4715 | She-196 | First in Class Hypoglycemic Agent with Extra-Strong Action, increasing insulin sensitivity, improving glucose tolerance, reducing fasted insulin level and insulin sensitivity, decreasing total body and interscapular fat mass and also increasing the activi |
|
| DCC4716 | Sherpa Bmi-135 | Novel Selective Human ER Partial Agonist (ShERPA) |
|
| DCC4717 | Sheta2 | Selective inhibitor of cancer cell growth, exerting chemoprevention activity without evidence of toxicity |
|
| DCC4718 | Sh-i-14 | Novel Inhibitor of Phospho-STAT3 Through Induction of Protein Tyrosine Phosphatase PTPN6 |
|
| DCC4719 | Shield-2 | Novel potent stabilizing ligand for FKBP-derived destabilizing domains |
|
| DCC4720 | Ship-2a | Cystathione gamma lyase (CSE) inhibitor, inhibiting H2S production and L-cysteine-induced relaxation of rat aortic rings ex vivo |
|
| DCC4721 | Showdomycin | Antineoplastic antibiotic |
|
| DCC4722 | Shp2 Inhibitor C21 | Inhibitor of shp2 protein tyrosine phosphatase (PTP) |
|
| DCC4723 | Shr0687 | Highly Potent and Peripheral Nervous System-Restricted KOR Agonist |
|
| DCC4724 | Sibopirdine | Novel cognitive enhancer; Nootropic agent |
|
| DCC4725 | Sid-24784551 | Novel direct HIV-1 Nef antagonist with antiretroviral activity |
|
| DCC4726 | Sid-7977382 | Novel Complement Factor C1 Inhibitor |
|
| DCC4727 | Silagaba132 | Silicon-Containing GABA Derivative, Treating Neuropathic Pain without Central-Nervous-System-Related Side Effects |
|
| DCC4728 | Silagaba161 | Silicon-Containing GABA Derivative, Treating Neuropathic Pain without Central-Nervous-System-Related Side Effects |
|
| DCC4729 | Sila-ibuprofen | Novel COX-I and COX-II inhibitor with four times higher solubility in physiological media and a lower melting enthalpy than ibuprofen |
|
| DCC4730 | Simfibrate | Peroxisome proliferator |
|
| DCC4731 | Sinapine Sulfate | Antioxidant and antimicrobial agent, counteracting mitochondrial oxidative stress in cardiomyocytes |
|
| DCC4732 | Sipi-6360 | Novel D2/5-HT2A Receptor Dual Antagonist |
|
| DCC4733 | Sipi-7623 | Novel farnesoid X receptor antagonist |
|
| DCC4734 | Sirt1-a2 | Novel SIRT1 Activator |
|
| DCC4735 | Sirt1-enhancer-a03 | First-in-class apolipoprotein E4 (ApoE4)-targeted sirtuin1 (SirT1) enhancer, normalizing sirtuin 1 levels and improving cognition in an Alzheimer's disease mouse model |
|
